+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Septic Shock - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • June 2022
  • Region: Global
  • DelveInsight
  • ID: 4037644
This Septic Shock - Pipeline Insight, 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Septic Shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Septic Shock Understanding

Septic Shock: Overview

Sepsis syndromes span a clinical continuum with variable prognoses. Septic shock, the most severe complication of sepsis, carries a high mortality. Septic shock occurs in response to an inciting agent, which causes both pro-inflammatory and anti-inflammatory immune system activation. This occurs in concert with the activation of monocytes, macrophages, and neutrophils that interact with the endothelium through pathogen recognition receptors and lead to further involvement of cytokines, proteases, kinins, reactive oxygen species, and nitric oxide. As the primary site of this response, the endothelium not only suffers microvascular injury but also activates the coagulation and complement cascades which further exacerbate the vascular injury, leading to capillary leakage. This cascade of events is responsible for the clinical signs and symptoms of sepsis and progression from sepsis to septic shock. Striking a balance between pro-inflammatory responses, which help eradicate the invading microorganism, and anti-inflammatory signals, which keep the inflammatory cascade in check, ultimately determines the degree of morbidity and/or mortality of patients with sepsis. Judicious and early antimicrobial administration, sepsis care bundle use, and early goal-directed therapies have significantly and positively impacted sepsis-related mortality. However, early identification remains the best therapeutic tool for sepsis treatment and management. This activity describes the evaluation and management of septic shock and highlights the role of the interprofessional team in enhancing care delivery for affected patients.

Septic Shock - Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Septic Shock pipeline landscape is provided which includes the disease overview and Septic Shock treatment guidelines. The assessment part of the report embraces, in depth Septic Shock commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Septic Shock collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Septic Shock.
  • In the coming years, the Septic Shock market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Septic Shock R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Septic Shock treatment market. Several potential therapies for Septic Shock are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Septic Shock market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Septic Shock) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Septic Shock Emerging Drugs Chapters

This segment of the Septic Shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Septic Shock Emerging Drugs

Adrecizumab: Adrenomed

Adrecizumab is a proprietary humanized monoclonal adrenomedullin (ADM) specific antibody. This targeted therapy inhibits excessive circulating sepsis-induced ADM, stimulates protective effects on the endothelial barrier, and decreases interstitial vasodilatory effects. Currently, it is in Phase II stage of clinical trial evaluation to treat septic shock.

Nangibotide: Inotrem

Nangibotide is a chemically synthesized peptide and a specific TREM-1 inhibitor. Among other features, nangibotide modulation restores a balanced inflammatory response (immunomodulation) and improves survival (shock reversal). Inotrem's lead product candidate, nangibotide (LR12), has been granted access to the EMA's PRIority MEdicines (PRIME) scheme. The Food and Drug Administration has granted Fast Track designation to nangibotide for the treatment of septic shock.

Septic Shock: Therapeutic Assessment

This segment of the report provides insights about the different Septic Shock drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Septic Shock

There are approx. 10+ key companies which are developing the therapies for Septic Shock. The companies which have their Septic Shock drug candidates in the most advanced stage, i.e. phase II include, Adrenomed.


This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Septic Shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Septic Shock: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Septic Shock therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Septic Shock drugs.

Septic Shock Report Insights

  • Septic Shock Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Septic Shock Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Septic Shock drugs?
  • How many Septic Shock drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Septic Shock?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Septic Shock therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Septic Shock and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Adrenomed
  • Inotrem
  • Vivacelle Bio
  • Northern Therapeutics
  • La Jolla Pharmaceutical Company
  • Pharmazz
  • MYND Life Sciences

Key Players

  • Adrecizumab
  • Nangibotide
  • VBI-S
  • GEM00220
  • LJPC-501
  • Centhaquine

This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Septic Shock: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Septic Shock - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Adrecizumab: Adrenomed
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

GEM00220: Northern Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products
  • Comparative Analysis

Research programme: mycogene modulators: MYND Life Sciences
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Septic Shock Key CompaniesSeptic Shock Key ProductsSeptic Shock - Unmet NeedsSeptic Shock - Market Drivers and BarriersSeptic Shock - Future Perspectives and ConclusionSeptic Shock Analyst ViewsSeptic Shock Key CompaniesAppendix

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Adrenomed
  • Inotrem
  • Vivacelle Bio
  • Northern Therapeutics
  • La Jolla Pharmaceutical Company
  • Pharmazz
  • MYND Life Sciences